Underlying data for 'Risk Factors and Mortality Outcomes of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Bacteremia: A Retrospective Cohort Study from Two Indonesian Referral Hospitals'

This is database of retrospective cohort study to evaluate for the Risk Factors and Mortality Outcomes of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Bacteremia patients. The sample was conducted using the medical records of all inpatients from January to December 2019 at two referral hospitals in Jakarta, Indonesia, namely Cipto Mangunkusumo National Hospital and Persahabatan Central General Hospital. This study is approved by the Ethics Commission of The National Institute of Health Research and Development (LB.02.01/2/KE.184/2018), the Health Research Ethics Committee of the Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Hospital (KET-169/UN2.F1/ETIK/PPM.00.02/2022), and the Health Research Ethics Committee of Persahabatan Central General Hospital (42/KEPK-RSUPP/07/2018). The target population was patients with positive E. coli blood cultures which were taken once during hospitalization in all age groups. Patients who were treated for less than 48 hours, had negative E. coli blood cultures or with incomplete medical record data were excluded. Positive E. coli blood cultures were phenotypically differentiated into ESBL- and non-ESBL-producing colonies using the VITEK®2 compact system algorithm (bioMérieux, France). Patient characteristics, length of stay, source of infection, comorbidity, and several risk factor variables for ESBL-producing E. coli infection including age, history of antibiotic therapy, utilization of medical devices, Charlson Comorbidity Index (CCI), and history of hospitalization.

本数据集为一项回顾性队列研究数据库，用于评估菌血症患者中产超广谱β-内酰胺酶（Extended-Spectrum Beta-Lactamase-Producing, ESBL）大肠埃希菌（Escherichia coli, E. coli）感染的危险因素与死亡结局。本研究样本取自印度尼西亚雅加达两家转诊医院——西普托·曼昆苏莫莫国立医院（Cipto Mangunkusumo National Hospital）与珀萨哈巴坦中央综合医院（Persahabatan Central General Hospital）2019年1月至12月期间的全部住院患者病历。本研究已获得三项伦理批准：印度尼西亚国家卫生研究与发展机构伦理委员会（批准文号：LB.02.01/2/KE.184/2018）、印度尼西亚大学医学院-西普托·曼昆苏莫莫国立医院卫生研究伦理委员会（批准文号：KET-169/UN2.F1/ETIK/PPM.00.02/2022），以及珀萨哈巴坦中央综合医院卫生研究伦理委员会（批准文号：42/KEPK-RSUPP/07/2018）。本研究的目标人群为各年龄段中，住院期间单次采血培养结果为大肠埃希菌阳性的患者。排除标准如下：住院治疗时长不足48小时者、大肠埃希菌血培养结果阴性者，以及病历资料不完整者。研究人员采用法国生物梅里埃（bioMérieux）公司的VITEK®2 compact全自动微生物分析系统算法，将大肠埃希菌血培养阳性菌株表型分为产ESBL与非产ESBL菌株。本研究收集的变量包括：患者基线特征、住院时长、感染来源、合并症，以及产ESBL大肠埃希菌感染的多项危险因素变量，具体涵盖年龄、抗菌药物治疗史、医疗装置使用情况、查尔森合并症指数（Charlson Comorbidity Index, CCI）与住院史。